Price Action Don’t Lie: Is Buying Stock Like K2M Group Holdings Inc After Such Increase Winning Strategy?

Price Action Don't Lie: Is Buying Stock Like K2M Group Holdings Inc After Such Increase Winning Strategy?

The stock of K2M Group Holdings Inc (NASDAQ:KTWO) is a huge mover today! About 190,810 shares traded hands. K2M Group Holdings Inc (NASDAQ:KTWO) has risen 38.35% since March 7, 2016 and is uptrending. It has outperformed by 30.75% the S&P500.
The move comes after 8 months positive chart setup for the $839.56 million company. It was reported on Oct, 10 by Barchart.com. We have $27.90 PT which if reached, will make NASDAQ:KTWO worth $352.62 million more.

Analysts await K2M Group Holdings Inc (NASDAQ:KTWO) to report earnings on November, 1. They expect $-0.31 EPS, down 55.00% or $0.11 from last year’s $-0.2 per share. After $-0.27 actual EPS reported by K2M Group Holdings Inc for the previous quarter, Wall Street now forecasts 14.81% negative EPS growth.

K2M Group Holdings Inc (NASDAQ:KTWO) Ratings Coverage

Out of 7 analysts covering K2M Group Holdings (NASDAQ:KTWO), 6 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 86% are positive. K2M Group Holdings has been the topic of 10 analyst reports since August 5, 2015 according to StockzIntelligence Inc. JMP Securities initiated the shares of KTWO in a report on Friday, April 8 with “Market Outperform” rating. On Thursday, August 4 the stock rating was maintained by Barclays Capital with “Overweight”. Northland Capital downgraded the stock to “Market Perform” rating in Tuesday, May 3 report. UBS initiated the shares of KTWO in a report on Tuesday, September 22 with “Buy” rating. Gabelli initiated K2M Group Holdings Inc (NASDAQ:KTWO) on Friday, September 16 with “Buy” rating. The rating was maintained by Piper Jaffray with “Buy” on Wednesday, August 5. The firm earned “Strong Buy” rating on Monday, May 23 by Needham. Piper Jaffray maintained it with “Overweight” rating and $29 target price in Thursday, August 27 report. Needham maintained the stock with “Buy” rating in Wednesday, November 4 report. The stock of K2M Group Holdings Inc (NASDAQ:KTWO) earned “Outperform” rating by Oppenheimer on Tuesday, July 19.

According to Zacks Investment Research, “K2M Group Holdings, Inc. is a global medical device company. The Company is focused on designing, developing and commercializing complex spine and minimally invasive spine technologies and techniques. Its products consist of implants, disposables and instruments which are marketed and sold primarily to hospitals for use by spine surgeons. The Company’s products include Complex Spine, Minimally Invasive Spine and Degenerative Spine. Its technologies include MESA, Rail 4D, Deformity Cricket, SERENGETI, RAVINE, EVEREST and tifix. K2M Group Holdings, Inc. is headquartered in Leesburg, Virginia.”

More recent K2M Group Holdings Inc (NASDAQ:KTWO) news were published by: Bizjournals.com which released: “K2M Group Holdings Inc.: On the front edge of 3-D printing (Video)” on September 23, 2016. Also Marketwatch.com published the news titled: “K2M Group started at outperform with $23 stock price target at Oppenheimer” on May 07, 2014. Quotes.Wsj.com‘s news article titled: “News K2M Group Holdings Inc.KTWO” with publication date: May 03, 2014 was also an interesting one.

KTWO Company Profile

K2M Group Holdings, Inc., incorporated on June 29, 2010, is a medical device firm focused on designing, developing and commercializing spine technologies and techniques. The Company’s spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor. The Firm is engaged in designing, development and commercialization of products for patients suffering from degenerative spinal conditions. The Company’s products consist of implants, disposables and instruments which are marketed and sold primarily to hospitals for use by spine surgeons. The Company’s product portfolio contains over 70 product lines that are used in spine surgeries, minimally invasive spine (MIS) and degenerative surgeries. It markets or sells its products in the United States and over 36 other countries.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment